RGN抗体;RGN Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of CDC25 in rat Brain lysates using CDC25 antibody.    

  
  

The RGN antibody, targeting the protein regucalcin (RGN), has garnered attention in biomedical research due to regucalcin's multifunctional roles in cellular regulation. Regucalcin, also known as senescence marker protein 30 (SMP30), is a calcium-binding protein highly expressed in liver and kidney tissues. It modulates intracellular calcium homeostasis, oxidative stress responses, and apoptosis, implicating it in aging, metabolic disorders, and cancer. RGN antibodies, primarily monoclonal or polyclonal, are essential tools for detecting regucalcin in immunoassays, Western blotting, and immunohistochemistry, enabling studies on its tissue distribution and expression changes under pathological conditions.

Research using RGN antibodies has linked regucalcin deficiency to accelerated aging, hepatic dysfunction, and tumor progression. For instance, reduced regucalcin levels correlate with neurodegenerative diseases and diabetes, suggesting therapeutic potential. In oncology, regucalcin may act as a tumor suppressor, with RGN antibodies aiding in profiling its downregulation in malignancies.

Despite progress, challenges remain in standardizing antibody specificity and understanding regucalcin's precise mechanisms. Ongoing work focuses on developing high-affinity RGN antibodies for diagnostic applications and exploring regucalcin-targeted therapies. This antibody continues to bridge gaps in understanding calcium-mediated signaling pathways and their implications in disease.